DUBLIN, June 14, 2016 /PRNewswire/ -- Allergan plc
(NYSE: AGN), a leading global pharmaceutical company, today
announced its support of two new caregiver initiatives, a public
service announcement (PSA) and a caregiver resource website.
Allergan partnered with the Alzheimer's Foundation of America (AFA)
and Kim Campbell—wife of country music legend, Glen Campbell, who is battling Alzheimer's
disease—on a PSA to educate caregivers and family members about the
signs and symptoms of moderate stage Alzheimer's disease and where
to turn for support. Television and radio stations across the U.S.
are airing the PSA, which also can be viewed on the AFA
website.
Logo -
http://photos.prnewswire.com/prnh/20150612/222796LOGO
"As the Campbell family understands firsthand, it is critical
that families of people with Alzheimer's disease know where to turn
for help and support," said Charles J.
Fuschillo, Jr., AFA's president and chief executive officer.
"Care and support are how we can make a difference in helping the
millions of individuals living with Alzheimer's and for their
families."
Allergan also announced the launch of a new caregiver resource
website, CaringforAlzheimers.net. The site is an online resource
where caregivers can find out more information about the symptoms
of Alzheimer's disease. The site features tools that caregivers can
use to effectively communicate with their loved one's doctor,
including a symptoms tracker that can be filled out to help track
disease progression.
"Alzheimer's disease is a progressive, neurodegenerative
disorder that is complex, particularly when patients enter the
moderate stage of the disease," says Gavin
Corcoran, M.D., chief medical officer. "At Allergan, we're
proud to support programs that provide more information and offer
resources to guide patients and caregivers as they navigate the
disease."
More than 5.1 million people in the U.S. may have Alzheimer's
disease.1 According to a U.S.-based survey, nearly 50
percent of patients with Alzheimer's disease are already in the
moderate to severe stages at the time of diagnosis.2 For
more information about the initiatives, visit AlzFdn.org or
CaringforAlzheimers.net.
About Allergan
Allergan plc (NYSE: AGN),
headquartered in Dublin, Ireland,
is a unique, global pharmaceutical company and a leader in a new
industry model – Growth Pharma. Allergan is focused on
developing, manufacturing and commercializing innovative branded
pharmaceuticals, high-quality generic and over-the-counter
medicines and biologic products for patients around the world.
Allergan markets a portfolio of best-in-class products that
provide valuable treatments for the central nervous system, eye
care, medical aesthetics, gastroenterology, women's health,
urology, cardiovascular and anti-infective therapeutic categories,
and operates the world's third-largest global generics business,
providing patients around the globe with increased access to
affordable, high-quality medicines. Allergan is an industry leader
in research and development, with one of the broadest development
pipelines in the pharmaceutical industry and a leading position in
the submission of generic product applications globally.
With commercial operations in approximately 100 countries,
Allergan is committed to working with physicians, healthcare
providers and patients to deliver innovative and meaningful
treatments that help people around the world live longer, healthier
lives.
For more information, visit Allergan's website at
www.allergan.com.
About Alzheimer's Foundation of America (AFA)
The
Alzheimer's Foundation of America, based in New York, is a non-profit organization that
unites more than 2,500 member organizations nationwide with the
goal of providing optimal care and services to individuals living
with dementia, and to their caregivers and families. Its services
include a national, toll-free helpline (866-232-8484) staffed by
licensed social workers, educational materials, a free quarterly
magazine for caregivers and "AFA Partners in Care" dementia care
training for healthcare professionals. For more information about
AFA, call 866-232-8484, visit www.alzfdn.org, follow us on Twitter,
or connect with us on Facebook or LinkedIn.
Forward-Looking Statement
Statements contained in
this press release that refer to future events or other
non-historical facts are forward-looking statements that reflect
Allergan's current perspective of existing trends and information
as of the date of this release. Except as expressly required by
law, Allergan disclaims any intent or obligation to update these
forward-looking statements. Actual results may differ materially
from Allergan's current expectations depending upon a number of
factors affecting Allergan's business. These factors include, among
others, the difficulty of predicting the timing or outcome of FDA
approvals or actions, if any; the impact of competitive products
and pricing; market acceptance of and continued demand for
Allergan's products; difficulties or delays in manufacturing; and
other risks and uncertainties detailed in Allergan's periodic
public filings with the Securities and Exchange Commission,
including but not limited to Allergan's Annual Report on Form 10-K
for the year ended March 31,
2016(certain of such periodic public filings having been
filed under the "Actavis plc" name). Except as expressly required
by law, Allergan disclaims any intent or obligation to update these
forward-looking statements.
1. "About Alzheimer's Disease: Statistics" Alzheimer's
Foundation of America. Accessed June 2016.
http://www.alzfdn.org/AboutAlzheimers/statistics.html.
2. "Alzheimer's Disease Physician Study." GfK Healthcare. 2013.
CONTACTS:
Media:
Fran DeSena
(973) 517-3132
Mark Marmur
(862) 261-7558
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/allergan-reaches-out-to-family-caregivers-of-people-with-alzheimers-disease-with-new-psa-website-300284125.html
SOURCE Allergan plc